An interventional study of Filter Placed in Venous Thromboembolism, sponsored by University of California, San Francisco. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-12.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Treatment
This research study is a prospective randomized trial evaluating the relative safety of two inferior vena cava (IVC) filters used to prevent the migration of potentially dangerous deadly blood clots from the legs to the lung in patients who cannot take blood thinners. All eligible patients will have been ordered to have a IVC filter placed by their primary medical team and filters will be placed in these patients whether or not they wish to participate in this trial as part of standard of care. The investigators will follow up with patients 30 days after IVC filter placement and ask them to come back for filter removal if medically appropriate. If removal is not medically appropriate in 30 days, the investigators will attempt to schedule removal every 30 days after initial placement.
Primary outcome measures will be IVC filter complications such as filter penetration through the IVC wall and into other organs, filter tilt, filter migration, filter fracture and clots formed within the filter. All of these are reported complications of all IVC filters.
The research also aims to improve the standard of care for IVC filter patient follow up as the FDA and Society of Interventional Radiology recommend that IVC filters be removed as soon as it is safe to do so.
Hypothesis:
The investigators hypothesize that there is no significant difference in efficacy and complication rate between the Option and the Denali filter.
This is a prospective, randomized trial comparing two FDA-approved inferior vena cava filters, the Denali retrievable IVC filter (Bard Peripheral Vascular Inc., Tempe, AZ) and the Option Elite (Argon Medical, Athens, Texas).
Patients scheduled for IVC filter placement at UCSF Department of Interventional Radiology (IR) will be asked by the IR physician performing the procedure at either UCSF Mt. Zion or Moffitt hospital if they wish to participate in this prospective, randomized study. Recruitment will be conducted by the physicians performing the IR procedures only. No additional recruitment calls, emails, posters or web pages are necessary. All procedures and the randomization to one of the two experimental groups will be carefully explained before obtaining signed written consent.
Screening:
Screening will be conducted by the IR physician prior to the placement of the IVC filters. Since this is a standard of care study, patients who are recommended for IVC filter placement and are scheduled for the procedure are generally eligible.
The screening procedures are part of routine care before IVC filter placement and would be done even if patients did not join the study.
The study doctor will review the results of most recent routine care imaging scans (CT or MRI) of the abdomen and pelvis. This is done to confirm that the diameter of IVC is no wider than 2.8cm. Both filters are FDA-approved to be placed in an IVC with maximal diameter of 2.8cm.
The study doctor will also review ultrasound of the lower extremity, when available, to confirm that a blood clot was in fact present prior to performing the study. This ensures that patients who present for IVC filter placement are screened properly.
The following screening procedures should be done within 12 days before the IVC filter placement procedure as part of the standard of care.
After Enrollment:
If the screening procedures show that the patient is eligible and consents to take part in the study, IVC filter placement will occur after randomization.
After enrollment, the following procedures will be done during the study: Just as with screening, all of these procedures are part of regular IVC filter placement care.
Randomization:
Randomization will occur on the day of procedure or prior clinic visit with IR physician to either the Denali or Option IVC filter. All IR attending physicians on the protocol are familiar with placement of either filter type. Prior to opening study to accrual, 75 sealed security envelopes with the word Denali printed on a card inside and 75 sealed security envelopes with the word Option will be assembled by IR staff not involved in the research. The envelopes will be mixed up and placed in a bag. Computerized randomization programs and tables were considered but we feel the envelopes will work best as there may be limited time after patient is consented and procedure begins. This is especially true as some filters are placed emergently. Previous IR studies have used this randomization technique with great success.
Filter Placement:
Placement of an IVC filter involves the insertion of a plastic tube (catheter) into a vein in the neck. Some numbing medicine (Lidocaine) will be injected in the skin over the vein before the catheter is inserted. Intravenous medications will be given to induce moderate sedation (Fentanyl for analgesic and Versed for moderate sedation). Once the catheter has been placed into the vein, it will be advanced into the IVC. Once in correct position, x-ray contrast material (x-ray dye-Omnipaque 350) will be injected through the catheter and x-ray pictures taken. A series of x-ray pictures will be obtained of the IVC. These pictures are taken as part of standard of care to determine the position of the renal veins with respect to the IVC. The top of the filter must sit below the renal veins so it does not cause obstruction of the renal veins. In addition, pictures of the IVC are taken to serve as another tool in measuring the diameter of the IVC to make sure the diameter of the IVC is less than 2.8cm. This is particularly important in situations when a CT or MRI of the abdomen and pelvis is not available to have reviewed prior to the procedure. Once pictures are obtained and it is made certain that the IVC diameter is less than 2.8cm, the filter will be inserted through the catheter, and placed below the renal veins. During the placement procedure, positioning of the filter will be monitored with x-ray pictures. At the completion of the procedure the catheter will be removed and pressure will be applied to the insertion site until the bleeding has stopped. All of this is part of routine standard of care for placement of the filter. The doctor performing the procedure will be asked to complete a short questionnaire after IVC filter placement which will be attached to "Study Documents".
Follow-Up:
After the IVC filter placement procedure patient status will be followed by the interventional radiology doctors.
Per standard of care after IVC filter placement, patient will be monitored in the hospital for up to 1 hour after the procedure. If patient is in stable condition and sedation has resolved, they will return home the same day or returned to their hospital rooms.
A tentative appointment for follow up and filter retrieval will be ordered by IR physician at time of filter placement in APEX. This will ensure that scheduling and study staff will be aware that further patient and primary care follow-up is required.
Patient primary care physician and/or relevant medical staff will be telephoned one month after IVC filter placement to determine if patient is medically stable and suitable for IVC filter removal.
If IR and other doctors agree that IVC filter removal is recommended, patient will be scheduled to return for follow-up imaging and filter retrieval. If patient is not medically stable or still at high risk for blood clots, we will attempt to schedule a follow up one month later. Close contact with primary physician and patient will be maintained to ensure that filter is removed as soon as possible. APEX scheduling will be used to make sure follow up is performed at regular intervals.
At follow-up appointment these routine tests per standard of care before IVC filter removal will be performed:
708 studies on the registry are indexed under Venous Thromboembolism; 152 are open to participants now.
This study's enrollment of 45 is below the median of 257 across 390 interventional studies indexed under Venous Thromboembolism.
Browse Venous Thromboembolism studies →University of California, San Francisco is the lead sponsor of 2,164 studies on the registry; 368 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 199 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Denali IVC Filter
Device: Filter Placed
Option Elite IVC Filter
Device: Filter Placed
IVC: Filter Penetration
Using imaging analysis, patients will resume their standard care as normal but be encouraged to come back in 30 days for imaging followup and removal. other than that we will look at all available CT and xray imaging that clearly shows the filter and IVC vessel walls. We will count how many participants have penetration of the IVC greater than 3mm and the number of days since placement at imaging timepoints. The number of struts or hooks per filter with penetration will also be recorded.
Time frame: in dwelling time in 1 day after filter insertion up to 3 years.
Computerized Tomography (CT) Studies With IVC Penetration
All CT studies with IVC penetration ≥ 3 mm, (%)
Time frame: 0-1733 days
Number of Participants With IVC Filter Migration
The number of participants with IVC filter migration in terms of distance migrated from initial placement location 30 days after filter placement will be assessed radiographically.
Time frame: 30 days
IVC Filter Tilt
number of participants with tilt of greater than 15 degrees in any CT imaging studies after filter placement and before removal of filter or study endpoint reached.
Time frame: 0-365 days post placement until project closure or patient endpoint reached
IVC Filter Fracture
Fracture of the component legs and struts of the IVC filter will be determined radiographically 30 days after placement.
Time frame: 30 days
IVC Filter Clot
Thrombus (or clot) formed in the IVC filter 30 days after placement will be assessed radiographically.
Time frame: 30 days
IVC Filter Improved Patient Follow Up and Prompt Filter Removal
The research also aims to improve the standard of care for IVC filter patient follow up as the FDA and Society of Interventional Radiology (SIR) recommend that IVC filters be removed as soon as it is safe to do so. Ideally filters will be imaged and removed after 30 days but in some cases patients will need filters to remain in place longer. We will make every effort to encourage patients and their medical team to return for follow up imaging and filter removal as soon as is deemed medically safe.
Time frame: Number of participants who had filters removed after 30 days up to 1 year
IVC Filter Improved Patient Follow Up and Prompt Filter Removal: Number of Days
The research also aims to improve the standard of care for IVC filter patient follow up as the FDA and Society of Interventional Radiology (SIR) recommend that IVC filters be removed as soon as it is safe to do so. Ideally filters will be imaged and removed after 30 days but in some cases patients will need filters to remain in place longer. We will make every effort to encourage patients and their medical team to return for follow up imaging and filter removal as soon as is deemed medically safe.
Time frame: Number of participants who had filters removed after 30 days up to 1 year
From April 2014-May 2016, patients coming to University of California, San Francisco Interventional Radiology (IR) with a MD referral for an Inferior Vena Cava (IVC) filter were invited to join a study of two FDA approved filters. After informed consent, subjects were randomized 1:1 to receive either a Denali or Option Elite filter.
| Milestone | Denali | Option Elite |
|---|---|---|
| Started | 24 | 21 |
| Filter retrieval | 17 | 16 |
| Signed icf but did not enroll | 0 | 1 |
| Filter ruled to be permanent | 2 | 2 |
| Lost to follow up | 2 | 1 |
| Death (before removal) | 3 | 4 |
| Complicated retrieval | 2 | 0 |
| Failed retrieval (referred elsewhere) | 1 | 0 |
| Completed | 17 | 16 |
| Not completed | 7 | 5 |
| Withdrew: Death | 3 | 4 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Failed retrieval | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
Using imaging analysis, patients will resume their standard care as normal but be encouraged to come back in 30 days for imaging followup and removal. other than that we will look at all available CT and xray imaging that clearly shows the filter and IVC vessel walls. We will count how many participants have penetration of the IVC greater than 3mm and the number of days since placement at imaging timepoints. The number of struts or hooks per filter with penetration will also be recorded.
| Participants | Denali | Option |
|---|---|---|
| IVC: Filter Penetration | 24 | 20 |
All CT studies with IVC penetration ≥ 3 mm, (%)
| Penetrating filter struts | Denali | Option |
|---|---|---|
| Computerized Tomography (CT) Studies With IVC Penetration | 0 | 0 |
The number of participants with IVC filter migration in terms of distance migrated from initial placement location 30 days after filter placement will be assessed radiographically.
| Participants | Denali | Option |
|---|---|---|
| Number of Participants With IVC Filter Migration | 0 | 0 |
number of participants with tilt of greater than 15 degrees in any CT imaging studies after filter placement and before removal of filter or study endpoint reached.
| participants | Denali Filter Tilt | Option Filter Tilt |
|---|---|---|
| IVC Filter Tilt | 0 | 0 |
Fracture of the component legs and struts of the IVC filter will be determined radiographically 30 days after placement.
| Participants | Denali | Option |
|---|---|---|
| IVC Filter Fracture | 0 | 0 |
Thrombus (or clot) formed in the IVC filter 30 days after placement will be assessed radiographically.
| Participants | Denali | Option |
|---|---|---|
| IVC Filter Clot | 2 | 2 |
The research also aims to improve the standard of care for IVC filter patient follow up as the FDA and Society of Interventional Radiology (SIR) recommend that IVC filters be removed as soon as it is safe to do so. Ideally filters will be imaged and removed after 30 days but in some cases patients will need filters to remain in place longer. We will make every effort to encourage patients and their medical team to return for follow up imaging and filter removal as soon as is deemed medically safe.
| Filter | Denali | Option |
|---|---|---|
| IVC Filter Improved Patient Follow Up and Prompt Filter Removal | 17 | 16 |
The research also aims to improve the standard of care for IVC filter patient follow up as the FDA and Society of Interventional Radiology (SIR) recommend that IVC filters be removed as soon as it is safe to do so. Ideally filters will be imaged and removed after 30 days but in some cases patients will need filters to remain in place longer. We will make every effort to encourage patients and their medical team to return for follow up imaging and filter removal as soon as is deemed medically safe.
| Days | Denali | Option |
|---|---|---|
| IVC Filter Improved Patient Follow Up and Prompt Filter Removal: Number of Days | 161.7 | 130.8 |
Collected over During the study, site personnel will note any change in the condition(s) and the occurrence and nature of any adverse events. For 30 days after removal of IVC filter or until study endpoint reached, patients will be followed for any adverse event that could be related to the IVC filter or removal.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denali | 4/24 (16.7%) | 0/24 (0%) | 0/24 (0%) |
| Option | 3/20 (15%) | 0/20 (0%) | 0/20 (0%) |
| Event | Denali | Option |
|---|---|---|
| Filters with IVC penetration ≥ 3 mmVascular disorders | 0/24 | 0/20 |
| All CTs with IVC penetrationVascular disorders | 0/24 | 0/20 |
| Filter FractureVascular disorders | 0/24 | 0/20 |
| Filter movementVascular disorders | 0/24 | 0/20 |
| Filter Tilt > or = 15 deg.Vascular disorders | 0/24 | 0/20 |
| All CT studies with TiltVascular disorders | 0/24 | 0/20 |
45 participants signed consent forms in the trial however one was withdrawn from the Option group due to physician's choice and in the Denali group one participant had two filters placed at different times.
| Age, Categorical(Participants) | Denali | Option | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 12 | 24 |
| >=65 years | 12 | 9 | 21 |
| Sex: Female, Male(Participants) | Denali | Option | Total |
|---|---|---|---|
| Female | 11 | 10 | 21 |
| Male | 13 | 11 | 24 |
| Race (NIH/OMB)(Participants) | Denali | Option | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 17 | 16 | 33 |
| More than one race | 4 | 3 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Denali | Option | Total |
|---|---|---|---|
| United States | 24 | 21 | 45 |
| Indication for filter placement(Participants) | Denali | Option | Total |
|---|---|---|---|
| VTE and contraindication to anticoagulation | 13 | 11 | 24 |
| Prophylactic (no current thromboembolic disease) | 8 | 8 | 16 |
| Failure to maintain anti coagulation | 1 | 1 | 2 |
| Recurrent Pulmonary Embolism Despite Therapy | 1 | 1 | 2 |
| Complication from Anti coagulation | 1 | 0 | 1 |
| Filter Indwelling Time(days since filter placement) | Denali | Option | Total |
|---|---|---|---|
| Mean | 378.7 (0 to 1647) | 277.1 (0 to 1733) | 331.3 (0 to 1733) |
Documents are hosted by the registry — open the source record to download them.
This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →